Overview
A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy
Status:
Enrolling by invitation
Enrolling by invitation
Trial end date:
2023-12-01
2023-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will evaluate the long-term efficacy and safety of AXS-12 in narcoleptic subjects with cataplexy and excessive daytime sleepiness (EDS).Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Axsome Therapeutics, Inc.Treatments:
Reboxetine
Criteria
Inclusion Criteria:- Completed the treatment period of Study AXS-12-301
- Willing and able to comply with the study requirements
Exclusion Criteria:
- Significant change in medical history or concomitant medications since enrolling in
the AXS-12-301 study which, in the opinion of the Investigator, would render the
subject unsuitable to receive AXS-12